Author: Kevin Grogan

Roche’s leukaemia drug Gazyva has shown significant benefit in a late-stage trial for refractory indolent non-Hodgkin’s lymphoma, meeting its primary endpoint early.

The push to make the UK a hotspot for life sciences received another boost at the end of last week with the inaugural Future of Healthcare Investor Forum bringing companies and financiers together at the London Stock Exchange.

The Japanese government has threatened Novartis with the suspension of its pharmaceuticals operations in the country for not reporting over 3,200 adverse effects cases.

Healthcare has featured predominantly in President Obama’s $4 trillion budget submitted to the US Congress and observers have focused upon plans to let the government negotiate the price of drugs, his precision medicines initiative and a proposal to tax the foreign earnings of firms such as Pfizer and Merck & Co.

A new clinical research study has been launched in the UK that will explore why the current gold standard biologics for people with rheumatoid arthritis do not work in around a third of patients.